GE HealthCare posts strong Q3 2026 results and lifts full‑year guidance while moving ahead with SOFIE acquisition
GE HealthCare reported third‑quarter 2026 revenue of $5.51 billion, up 7.2% year‑over‑year, with organic revenue growth of 6.2%. Adjusted earnings per share rose 25.1% to $1.34 and GAAP EPS increased 39.1% to $1.36. The company raised its full‑year 2026 adjusted EPS outlook to $4.95‑$5.05 and its organic revenue growth target to about 4%, and announced a pending cash acquisition of SOFIE Biosciences for $945 million, expected to close in the first half of 2027.
Why it matters
The higher guidance signals stronger profitability and cash generation, which could support a higher valuation and dividend capacity (the company noted a 14% dividend increase). The SOFIE acquisition expands GE HealthCare’s PET radiopharmaceutical supply chain in the U.S., potentially enhancing future revenue streams.
Key facts
- 1Q3 2026 revenue was $5.51 billion, a 7.2% YoY increase. zacks.com
- 2Organic revenue grew 6.2% in the quarter. stocktitan.net
- 3Adjusted EPS was $1.34, up 25.1% YoY. zacks.com
- 4GAAP EPS was $1.36, up 39.1% YoY. stocktitan.net
- 5Backlog reached $23.7 billion. stocktitan.net
- 6Free cash flow for the quarter was $793 million. investing.com
Summary written by AlphAI AI Desk from 20 of 20 sources. Not investment advice. Figures are as stated by the linked sources.